Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and …
Over the last 12 months, insiders at Aligos Therapeutics, Inc. have bought $0 and sold $0 worth of Aligos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aligos Therapeutics, Inc. have bought $13.13M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,933,601 shares for transaction amount of $6M was made by Nuechterlein Carole () on 2023‑10‑25.
2023-10-25 | Nuechterlein Carole | 7.93M 22.4566% | $0.76 | $6M | +4.10% | |||
2020-10-20 | Vivo Capital VIII, LLC | 10 percent owner | 550,000 1.9863% | $15.00 | $8.25M | +61.44% | ||
2020-10-20 | Novo Holdings A/S | 10 percent owner | 200,000 0.7223% | $15.00 | $3M | +61.44% | ||
2020-10-20 | Woiwode Thomas | director | 200,000 0.7223% | $15.00 | $3M | +61.44% | ||
2020-10-20 | Versant Venture Capital VI, L.P. | director | 400,000 1.4446% | $15.00 | $6M | +61.44% |
Nuechterlein Carole | 11025941 307.3098% | $126.14M | 1 | 0 | +4.1% | |
Vivo Capital VIII, LLC | 10 percent owner | 3116658 86.866% | $35.65M | 1 | 0 | +61.44% |
Novo Holdings A/S | 10 percent owner | 2614563 72.8719% | $29.91M | 1 | 0 | +61.44% |
Woiwode Thomas | director | 862444 24.0376% | $9.87M | 1 | 0 | +61.44% |
Versant Venture Capital VI, L.P. | director | 862444 24.0376% | $9.87M | 1 | 0 | +61.44% |
$4,273,853 | 101 | -36.67% | $40.54M | |
$77,062,892 | 41 | 13.96% | $38.79M | |
$140,938,207 | 36 | 14.75% | $43.63M | |
$241,165 | 22 | -16.72% | $38.37M | |
$167,476,357 | 20 | -1.54% | $41.08M |
Increased Positions | 22 | +78.57% | 436,981 | +24.19% |
Decreased Positions | 9 | -32.14% | 511,070 | -28.29% |
New Positions | 12 | New | 265,461 | New |
Sold Out Positions | 6 | Sold Out | 475,504 | Sold Out |
Total Postitions | 41 | +46.43% | 2M | -4.1% |
Adage Capital Partners Gp, L.L.C. | $5,483.00 | 10.83% | 325,000 | +106,187 | +48.53% | 2024-12-31 |
Ecor1 Capital, Llc | $4,312.00 | 8.52% | 255,573 | 0 | 0% | 2024-12-31 |
Deep Track Capital, Lp | $4,118.00 | 8.14% | 244,110 | 0 | 0% | 2024-12-31 |
Vivo Capital, Llc | $2,393.00 | 4.73% | 141,879 | 0 | 0% | 2024-12-31 |
Altitude Crest Partners Inc. | $1,920.00 | 3.79% | 113,787 | 0 | 0% | 2024-03-31 |
Vanguard Group Inc | $1,632.00 | 3.23% | 96,762 | +32,948 | +51.63% | 2024-12-31 |
Baker Bros. Advisors Lp | $1,401.00 | 2.77% | 83,055 | 0 | 0% | 2024-12-31 |
Hhlr Advisors, Ltd. | $1,286.00 | 2.54% | 76,247 | 0 | 0% | 2024-12-31 |
Trexquant Investment Lp | $1,165.00 | 2.3% | 69,050 | +69,050 | New | 2024-12-31 |
Ikarian Capital, Llc | $1,085.00 | 2.14% | 64,300 | +64,300 | New | 2024-12-31 |